Which patient is least likely to benefit from therapy with immunosuppressors?

• A. A patient with high levels of miR-30a-3p
• B. A patient with low levels of miR-30a-3p
• C. A patient with stable organ function
• D. A patient with previous transplant rejection

Answer: (A)

In the context of immunosuppressive therapy, the potential benefit of such treatments is often associated with a patient's immune response and the specific circumstances of their health condition. High levels of miR-30a-3p have been linked to a range of autoimmune and inflammatory responses. This microRNA can play a crucial role in regulating immune cell function and may indicate a heightened immune activity.

When immunosuppressors are administered, they aim to dampen the immune response. A patient with high levels of miR-30a-3p is likely to have an active immune response that could be exacerbated by inflammatory conditions. However, immunosuppressive therapy is generally more beneficial in patients who exhibit significant immune activity that needs to be moderated, such as those experiencing transplant rejection or unstable organ function.

In contrast, a patient with stable organ function may not require as aggressive an approach with immunosuppressants because their immune system is currently adequately managing organ integrity. Furthermore, a patient with low levels of miR-30a-3p may also be experiencing a less active immune state, which might indicate a lower immediate need for immunosuppression. Therefore, a patient with high levels of miR-30a-3p is least